611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
General, Central Obesity Linked to Specific Breast Cancer RiskProstate Cancer Symptoms Aren't Always ObviousCancer Treatment Can Affect Your Food PreferencesExpected Burden of Lung Cancer High for People Living With HIVNew Link Seen Between Gene Fusion and Bladder CancerSkin Cancer Prevention Strategies Needed in Work SettingsFDA Approves First Biosimilar Drug for CancerAliqopa Approved for Follicular LymphomaFibrous Dysplasia Associated With Increased Breast Cancer RiskU.S. Cancer Death Rate Continues to FallAACR Releases 2017 Cancer Progress ReportUSPSTF Backs Cervical Cancer Screening With Cytology or hrHPVMultivitamin Use May Cut Risk of Chemo-Induced NeuropathySurgeons Play Big Role in Women's Choices for Breast Cancer CareDabrafenib, Trametinib Beneficial in Resected MelanomaNew Guideline Aims to Help Doctors Diagnose Head, Neck MassesWidening Waistlines May Raise Women's Cancer RiskAdjuvant Nivolumab Tops Ipilimumab in MelanomaHPV Test Alone OK for Cervical Cancer Screening Over 30: Expert PanelCancer Drugs' High Prices Not Justified by Cost of Development, Study ContendsMedian Cost of Cancer Drug Development $648.0 MillionManaging Pain Can Be a Puzzle After Breast CancerImmune-Focused Drug May Be New Weapon Against Advanced MelanomaObamacare Paid Off for Poorer Cancer PatientsStrong Evidence for Healthy Lifestyle Reducing CRC RiskHere's the Recipe to Keep Colon Cancer at BayCRC Tumor Cells Exposed to Gut Bacteria Express ChemokinesUniversal Sequencing of Cancer Genes Ups Mutation DetectionMailed Invitations Increase CRC Screening CompletionInactivated Vaccinia Virus Shows Promise Against Advanced Cancer'Cancer Pen' Could Help Surgeons Spot Tumor Cells in SecondsCould the Zika Virus Help Battle a Deadly Brain Cancer?New Research Finds Value in PSA TestingHealth Tip: Diet and Activity May Help Prevent CancerFDA OKs Return of Once-Withdrawn Leukemia DrugLow Tumor Growth Rates During Active Surveillance of Thyroid CAScience Weighs in On How Fat Raises Cancer RiskFirst Gene Therapy Approved in U.S.Options Available for Estrogen Depletion After Breast CancerMoles Not Most Likely Spot for MelanomasAndrogen-Deprivation Therapy May Carry Cardiovascular RisksComputed Tomography Useful for Staging Head, Neck MelanomaCommon Treatment for Early Prostate Cancer May Carry Heart RiskCould Common Vitamin Supplements Raise Lung Cancer Risk?Females Show Better Response to CRT in Esophageal CancerOutdoor Nighttime Light Exposure Linked to Breast Cancer RiskArsenic Levels Higher in Patients With Nonmelanoma Skin CancersRadioiodine Therapy for Thyroid Cancer Doesn't Up Stroke RiskOne-Quarter With Early Breast Cancer Strongly Considers CPMFDA Approves New Treatment for Acute Lymphoblastic Leukemia
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

HPV Vaccine May Also Prevent Cancers Affecting Men

HealthDay News
by -- Robert Preidt
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The same vaccine that cuts the risk of cervical cancer in women might also lower the chances of head and neck cancers in men, new research suggests.

In addition to being linked to cervical cancer, the human papillomavirus (HPV) can cause cancers in the back of the throat, in an area known as the oropharynx. HPV is linked with about 70 percent of these types of cancers in the United States, and the rates of these cancers are rising dramatically, according to the U.S. Centers for Disease Control and Prevention.

The U.S. Food and Drug Administration has approved HPV vaccines for prevention of cervical, vulvar, vaginal and anal cancers in women, and anal cancers in men. However, the HPV vaccine hasn't been FDA-approved for prevention of head and neck cancers, because the vaccines have not been evaluated in clinical trials for that purpose.

"We don't know if there's a potential solution to these rising rates already existing on [drug] shelves," explained study author Dr. Maura Gillison. She is a professor of thoracic/head and neck medical oncology at the University of Texas MD Anderson Cancer Center.

"In the absence of that gold-standard clinical trial, we looked at data from a study that we've been conducting in my lab to address the question as to whether or not existing HPV vaccines could be altering oral HPV infections in the U.S. population," she explained in a Cancer Center news release.

The analysis of data from more than 2,600 Americans, aged 18 to 33, revealed that those who had received HPV vaccination were 88 percent less likely to have oral HPV infections than those who were not vaccinated.

Previous research has shown that HPV-related head and neck cancers are more common in men than women, so Gillison and her colleagues examined whether vaccination was associated with a reduced prevalence of oral HPV infection in men.

"When we compared the prevalence in vaccinated men to non-vaccinated men, we didn't detect any infections in vaccinated men. The data suggests that the vaccine may be reducing the prevalence of those infections by as high as 100 percent," Gillison said.

"We also wanted to determine, accounting for the low rates of vaccination, what proportion of infections could have been prevented," she said.

"We found that just under one million people would have HPV infections in this age group, but, unfortunately, because of low uptake of the vaccine, the burden of infection had only been reduced by 17 percent overall, and only 7 percent in men. We hope the burden of infection will decrease over time with increased vaccination," Gillison said.

The study, conducted while Gillison was at Ohio State University, is to be presented in June at the American Society of Clinical Oncology annual meeting, in Chicago. Research presented at medical meetings should be viewed as preliminary until published in a peer-reviewed journal.

More information

The Oral Cancer Foundation has more on HPV.